[go: up one dir, main page]

WO2000023062A3 - Solution et methode d'irrigation destinees a l'inhibition d'une douleur et d'une inflammation - Google Patents

Solution et methode d'irrigation destinees a l'inhibition d'une douleur et d'une inflammation Download PDF

Info

Publication number
WO2000023062A3
WO2000023062A3 PCT/US1999/024558 US9924558W WO0023062A3 WO 2000023062 A3 WO2000023062 A3 WO 2000023062A3 US 9924558 W US9924558 W US 9924558W WO 0023062 A3 WO0023062 A3 WO 0023062A3
Authority
WO
WIPO (PCT)
Prior art keywords
antagonist
pain
solution
inflammation
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/024558
Other languages
English (en)
Other versions
WO2000023062A2 (fr
Inventor
Gregory A Demopulos
Pamela P Palmer
Jeffrey M Herz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Omeros Corp
Original Assignee
Omeros Medical Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Medical Systems Inc filed Critical Omeros Medical Systems Inc
Priority to AU12149/00A priority Critical patent/AU1214900A/en
Priority to EP99970596A priority patent/EP1434573A2/fr
Publication of WO2000023062A2 publication Critical patent/WO2000023062A2/fr
Publication of WO2000023062A3 publication Critical patent/WO2000023062A3/fr
Priority to US09/839,633 priority patent/US20020028798A1/en
Priority to US09/839,633 priority patent/US7091181B2/en
Anticipated expiration legal-status Critical
Priority to US11/410,406 priority patent/US20060205657A1/en
Priority to US11/410,407 priority patent/US20060205658A1/en
Priority to US11/409,919 priority patent/US20060229588A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une méthode et une solution d'inhibition périopératoire de différentes sortes de manifestations de douleur et d'inflammation de plaies suite à des interventions chirurgicales, y compris des interventions buccales/dentaires. La solution contient de préférence au moins un agoniste de récepteurs neuronaux d'acétylcholine nicotinique et, éventuellement, de multiples autres agents d'inhibition de douleur et d'inflammation dans des concentrations diluées dans un excipient physiologique tel qu'un soluté salin ou un soluté lactate de Ringer. On applique la solution par irrigation continue d'une plaie lors d'une intervention chirurgicale afin de favoriser une inhibition préventive de la douleur tout en évitant des effets secondaires indésirables associés à l'administration par voie orale, intramusculaire, sous-cutanée ou intraveineuse de doses plus importantes de ces agents. De préférence, une solution d'inhibition de douleur et d'inflammation comprend un agoniste de récepteurs neuronaux d'acétylcholine nicotinique, un antagoniste de sérotonine2, un antagoniste de sérotonine3, un antagoniste d'histamine, un agoniste de sérotonine, un inhibiteur de cyclooxygénase, un antagoniste de neurokinine1, un antagoniste de neurokinine2, un antagoniste de purinocepteur, un élément d'ouverture du canal potassique sensible à l'ATP, un antagoniste du canal potassique, un antagoniste de bradykinine1, un antagoniste de bradikynine2 et un agoniste d'ν-opioïde.
PCT/US1999/024558 1994-12-12 1999-10-20 Solution et methode d'irrigation destinees a l'inhibition d'une douleur et d'une inflammation Ceased WO2000023062A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU12149/00A AU1214900A (en) 1998-10-20 1999-10-20 Irrigation solution and method for inhibition of pain and inflammation
EP99970596A EP1434573A2 (fr) 1998-10-20 1999-10-20 Solution et methode d'irrigation destinees a l'inhibition d'une douleur et d'une inflammation
US09/839,633 US20020028798A1 (en) 1995-12-12 2001-04-20 Irrigation solution and method for inhibition of pain and inflammation
US09/839,633 US7091181B2 (en) 1994-12-12 2001-04-20 Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
US11/410,406 US20060205657A1 (en) 1994-12-12 2006-04-24 Irrigation solution and method for inhibition of pain and inflammation
US11/410,407 US20060205658A1 (en) 1994-12-12 2006-04-24 Irrigation solution and method for inhibition of pain and inflammation
US11/409,919 US20060229588A1 (en) 1994-12-12 2006-04-24 Irrigation solution and method for inhibition of pain and inflammation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10504498P 1998-10-20 1998-10-20
US60/105,044 1998-10-20

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/024557 Continuation-In-Part WO2000023061A2 (fr) 1994-12-12 1999-10-20 Solution et methode d'irrigation destinees a l'inhibition d'une douleur et d'une inflammation

Related Child Applications (5)

Application Number Title Priority Date Filing Date
PCT/US1999/024625 Continuation-In-Part WO2000023072A1 (fr) 1994-12-12 1999-10-20 Solution d'irrigation contenant des inhibiteurs de mapk et son utilisation pour traiter la douleur et l'inflammation
US09/839,633 Continuation-In-Part US20020028798A1 (en) 1994-12-12 2001-04-20 Irrigation solution and method for inhibition of pain and inflammation
US11/409,919 Continuation-In-Part US20060229588A1 (en) 1994-12-12 2006-04-24 Irrigation solution and method for inhibition of pain and inflammation
US11/410,407 Continuation-In-Part US20060205658A1 (en) 1994-12-12 2006-04-24 Irrigation solution and method for inhibition of pain and inflammation
US11/410,406 Continuation-In-Part US20060205657A1 (en) 1994-12-12 2006-04-24 Irrigation solution and method for inhibition of pain and inflammation

Publications (2)

Publication Number Publication Date
WO2000023062A2 WO2000023062A2 (fr) 2000-04-27
WO2000023062A3 true WO2000023062A3 (fr) 2000-07-27

Family

ID=22303751

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/024558 Ceased WO2000023062A2 (fr) 1994-12-12 1999-10-20 Solution et methode d'irrigation destinees a l'inhibition d'une douleur et d'une inflammation

Country Status (3)

Country Link
EP (1) EP1434573A2 (fr)
AU (1) AU1214900A (fr)
WO (1) WO2000023062A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU781084B2 (en) * 1999-07-28 2005-05-05 Board Of Trustees Of The Leland Stanford Junior University Nicotine in therapeutic angiogenesis and vasculogenesis
US7838539B2 (en) 1999-07-28 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University Nicotine receptor agonists in stem cell and progenitor cell recruitment
WO2001008683A1 (fr) * 1999-07-28 2001-02-08 The Board Of Trustees Of The Leland Stanford Junior University Agoniste du recepteur de la nicotine, present dans une cellule souche, et mobilisation de cellules souches
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
CA2341952A1 (fr) 2001-03-23 2002-09-23 Universite Laval Agonistes du recepteur de la nicotine pour le traitement des maladies pulmonaires inflammatoires
US8557804B2 (en) 2002-03-25 2013-10-15 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US8039459B2 (en) 2004-07-15 2011-10-18 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
DK1534313T3 (da) 2002-07-30 2013-02-04 Omeros Corp Oftalmologiske irrigationsopløsninger og fremgangsmåde
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
KR20090112722A (ko) 2007-01-24 2009-10-28 글락소 그룹 리미티드 3,5-디아미노-6-(2,3-디클로로페닐)-1,2,4-트리아진 또는 ｒ(-)-2,4-디아미노-5-(2,3-디클로로페닐)-6-플루오로메틸 피리미딘 및 ｎｋ1을 포함하는 제약 조성물
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Intraocular Lenses Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
TWI705812B (zh) 2014-12-01 2020-10-01 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5820583A (en) * 1995-12-12 1998-10-13 Omeros Medical Systems, Inc. Surgical irrigation solution and method for inhibition of pain and inflammation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5820583A (en) * 1995-12-12 1998-10-13 Omeros Medical Systems, Inc. Surgical irrigation solution and method for inhibition of pain and inflammation

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BONDAREV V I ET AL: "[Disorders of immunoreactivity in acute cholecystitis in middle-aged and elderly patients and their correction in preventing postoperative complications]. Narusheniia immunoreaktivnosti pri ostrom kholetsistite u bol'nykh pozhilogo i starcheskogo vozrasta i ikh korrektsiia v profilatike posleoperats", KLINICHESKAIA KHIRURGIIA, (1990) (9) 27-9., XP002137213 *
CHIARI A, EISENACH J C: "ANTINOCICEPTIVE EFFECTS OF RJR 2403, A SELECTIVE NICOTINIC AGONIST, IN MALE AND FEMALE RATS.", FASEB JOURNAL, vol. 12, no. 4 PART 1, SUPP. [S], 17 March 1998 (1998-03-17), pages 920, XP000906769 *
DECKER ET AL: "Antinociceptive effects of the novel neuronal nicotinic acetylcholine receptor agonist, ABT-594, in mice", EUROPEAN JOURNAL OF PHARMACOLOGY,NL,AMSTERDAM, vol. 346, no. 1, 3 April 1998 (1998-04-03), pages 23 - 33-33, XP002110643, ISSN: 0014-2999 *
DONNELLY-ROBERTS ET AL: "ABT-594: a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS,US,AMERICAN SOCIETY FOR PHARMACOLOGY AND, vol. 285, no. 2, May 1998 (1998-05-01), pages 777 - 786-786, XP002105019, ISSN: 0022-3565 *
HOLLADAY ET AL: "Neuronal Nicotinic Acetylcholine Receptors as Targets for Drug Discovery", JOURNAL OF MEDICINAL CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 40, no. 26, 19 December 1997 (1997-12-19), pages 4169 - 4194-4194, XP002124847, ISSN: 0022-2623 *
ZHANG, XIAO. GONG, ZE-HUI. FASTH, KARL JOHAN. LANGSTROM, BENGT. NORDBER AGNETA: "INTERACTION OF THE NICOTINIC AGONIST (R,S)-3-PYRIDYL-1-METHYL-2-(3-PYRIDYL)-AZETIDINE (MPA) WITH NICOTINIC ACETYLCHOLINE RECEPTOR SUBTYPES EXPRESSED IN CELL LINES AND RAT CORTEX.", NEUROCHEM. INT., vol. 32, no. 5-6, 1998, pages 435 - 441, XP000905243 *

Also Published As

Publication number Publication date
AU1214900A (en) 2000-05-08
WO2000023062A2 (fr) 2000-04-27
EP1434573A2 (fr) 2004-07-07

Similar Documents

Publication Publication Date Title
WO2001007067A3 (fr) Solutions et procedes permettant d'inhiber la douleur, les inflammations et la degradation des cartilages
AU6397496A (en) Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis
WO2000023062A3 (fr) Solution et methode d'irrigation destinees a l'inhibition d'une douleur et d'une inflammation
CA2206119A1 (fr) Solution d'irrigation et procede d'inhibition de la douleur, de l'inflammation et des spasmes
WO2005044194A3 (fr) Traitement ou prevention de la neoplasie a l'aide d'un inhibiteur de la proteine hsp90
HU9402771D0 (en) Pharmaceutical compositions for wound healing and treatment of fibrotic disorders
WO2002019985A3 (fr) Procedes permettant d'enrayer une diminution de l'ecoulement d'un medicament par voie transdermique fondes sur l'inhibition de l'obturation du passage
ATE227124T1 (de) Behandlung von multipler sklerose (ms) und anderen demyelinisationserkrankungen unter verwendung von lofepramin in kombination mit l- phenylalamin, tyrosin oder tryptophan und evtl. einer vitamin b12-verbindung
WO2004091540A3 (fr) Methodes de traitement de la douleur et compositions associees
WO2000025745A3 (fr) Solution d'irrigation et methode pour l'inhibition de la douleur et de l'inflammation
WO1999063976A3 (fr) Traitement de diabetes
WO2003092606A3 (fr) Inhibiteurs de cholinesterase pour prevenir les blessures causees par des produits chimiques
RU94044356A (ru) Применение 2-фенил-3-ароилбензотиофенов для увеличения экспрессии тромбомодулина для ингибирования тромботического расстройства, для увеличения активации протеина с
DE69506686D1 (de) Verwendung von bis (amidinobenzidazolen) zur herstellung eines medikamentes für die hemmung der retroviral integrase
WO2000023066A3 (fr) Solution d'irrigation et procede d'inhibition de la douleur et de l'inflammation
WO2000023061A3 (fr) Solution et methode d'irrigation destinees a l'inhibition d'une douleur et d'une inflammation
HK1051485A1 (zh) 增生性疾病的治療
WO2000051582A3 (fr) Procedes de traitement de l'apnee et de troubles de l'apnee a l'aide de r(+) ondansetron optiquement pur
EP1563838A3 (fr) Solution d'irrigation et méthodes pour inhiber la douleur et l'inflammation
DE59410246D1 (de) Pharmazeutische formulierung zur prophylaxe bzw. vorbehandlung einer vergiftung durch phosphororganische cholinesterasehemmer
WO2002085292A3 (fr) Procede ameliore de traitement de manifestations aberrantes du tissu fibreux avec des preparations a base d'agent bloquant topique des canaux de calcium et composition amelioree utilisee dans ce traitement et son procede de fabrication ameliore
CZ223199A3 (cs) Použití inhibitorů COMT nebo jejich farmaceuticky vhodných solí nebo esterů pro výrobu léčiva k prevenci diabetických vaskulárních dysfunkcí
EP1051995A3 (fr) Agonistes de récepteur de 5HT 1 et un inhibiteur de la cyclooxygénase-2 pour le traitment de la migraine
WO2000032155A3 (fr) Compositions pour soins de la peau renfermant des sels de zinc et des retinoides
WO2003093415A3 (fr) Methodes utilisees dans le traitement et la prevention d'une infection par vih

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 12149

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 1999970596

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999970596

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11410407

Country of ref document: US

Ref document number: 11409919

Country of ref document: US

Ref document number: 11410406

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 11410407

Country of ref document: US

Ref document number: 11410406

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 11409919

Country of ref document: US